** Shares of Infinity Pharmaceuticals Inc fall ~43% to $0.12 premarket
** Co says it has terminated merger agreement with cancer therapy developer MEI Pharma Inc
** Says MEIP shareholders did not approve the merger with Infinity
** INFI says will explore strategic alternatives intended to realize the potential value of its lead drug candidate, eganelisib
** Eganelisib is being tested in a mid-stage study for a type of head and neck cancer -INFI
** INFI is entitled to reimbursement of certain expenses and fees of $1 mln from MEIP and also eligible to receive an additional $4 mln under the terms of the merger agreement - INFI
** Up to last close, INFI shares down ~60% this year
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.